Search results for "molecular microbiology"

Quantitative mRNA poly(A) tail length using standard polyacrylamide gel electrophoresis (PAGE). Easy, cost-effective benchtop method for QC as an alternative to mass spec analysis. Assess tail lengths above the limits of HPLC and LC-MS based methods.

InterPlay Adenoviral C-Terminal Vector, part of the InterPlay Adenoviral TAP System, combines Agilent’s unique tandem affinity purification system with our exclusive adenoviral gene delivery system for enhanced gene delivery to a broader range of mammalian cells, higher protein yields, and improved purification and analysis of endogenous interacting protein partners. 

InterPlay Adenoviral C-Terminal Vector, part of the InterPlay Adenoviral TAP System, combines Agilent’s unique tandem affinity purification system with our exclusive adenoviral gene delivery system for enhanced gene delivery to a broader range of mammalian cells, higher protein yields, and improved purification and analysis of endogenous interacting protein partners. 

High Quality Assays with Reproducible and Reliable Results

Tripling NMR sensitivity within the budget

Tryosine kinase inhibitor and epigenetic modifier; Inhibits PDGF, FGF, EGF, TGFß, SIRT1, and SIRT5

RHO/ROCK pathway inhibitor; Inhibits ROCK2

Fractalkine

BMP pathway inhibitor; Inhibits ALK1, ALK2, ALK3, and ALK6

The Dursan surface treatment uses a functionalized, silica-like coating for stainless steel frits and column tubes. The coating is very robust and thin (~400 - 1600nm) that modifies the contact surface your analytes meet to be metal-free and somewhat hydrophobic.  

Engineered, homologous, and specific target cells that enable screening for antibody-induced effector functions.

CN Bio supports R&D efforts via fast-track Drug Metabolism and Safety Toxicity Testing Services that deliver human translatable insights from lead candidates in a few weeks and at lower cost than animal studies. By accessing the Company’s expertise and advanced in vitro liver-on-chip models, these Services enable researchers to step beyond standard in-house laboratory workflows for better informed pre-clinical decisions.

Patients with underlying heart problems are more than four times as likely to die from COVID-19

Guest editorial: Brice Ezzouaouy, Senior Product Manager, Beckman Coulter Life Sciences, outlines the challenges of dimly expressed markers and presents a solution

Novel column technology designed to put disease research and drug development on a more productive and efficient path